GLP‑1 Coverage Slips
- Insurers have cut access to popular GLP‑1 obesity drugs, forcing patients to switch treatments or seek compounded options. ( ) - A GoodRx analysis found about 12 million people lost coverage for Zepbound and another 12 million for Wegovy from 2025–2026. (npr.org) - CMS is testing models like the BALANCE demonstration and a delayed Medicare pilot could still leave near‑term demand high. ( )
Health insurers are making it harder to get Wegovy and Zepbound, even as demand for the weight-loss drugs keeps rising. (npr.org) GoodRx found that from 2025 to 2026, about 12 million people lost some commercial coverage for Zepbound and another 12 million lost it for Wegovy. Its March 31 analysis said more than 41 million people now have no commercial coverage for Wegovy and more than 109 million have no commercial coverage for Zepbound. (goodrx.com) Even when plans still cover the drugs, access is often gated. GoodRx said more than 88% of commercially insured people with weight-loss coverage still face prior authorization, step therapy, or both. (goodrx.com) That leaves patients switching drugs, appealing denials, or paying cash. NPR reported that some patients turned to compounded versions after losing coverage, while others changed medicines to match what their plan would still pay for. (npr.org, wypr.org) The pullback comes as prescriptions keep climbing. GoodRx said fills have risen since the start of 2025 by 25% for Wegovy and 19% for Zepbound, and that Zepbound fills are up more than 600% since the beginning of 2024. (goodrx.com) The basic mismatch is cost. GoodRx said the average commercially insured Zepbound user can expect to pay more than $1,400 a year in copays, and people without insurance face retail costs above $1,400 per prescription. (goodrx.com) Medicare has its own split-screen. KFF said current law generally bars Medicare from covering drugs when they are prescribed specifically for weight loss, while Medicaid can cover them but is not required to do so. (kff.org) The Centers for Medicare & Medicaid Services is still testing a workaround called BALANCE, short for Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth. CMS said the model is meant to expand access to select GLP-1 drugs and lifestyle programs, with state Medicaid agencies able to join beginning in May 2026. (cms.gov) But the Medicare Part D piece hit a delay on April 21. KFF said CMS will not implement BALANCE in Medicare Part D in 2027 as first planned, and will instead extend the Medicare GLP-1 Bridge program through 2027. (kff.org) Reuters reported the delay followed insurer hesitation to join the pilot, and analysts said that is unlikely to cut near-term demand for the drugs. CMS still says eligible Medicare Part D beneficiaries will have access through the GLP-1 Bridge from July 1, 2026, to December 31, 2027. (usnews.com, cms.gov)
